The first drug targeting the cause of Huntington’s disease was safe and well-tolerated in its first human trial led by UCL scientists. It successfully lowered the level of the harmful huntingtin protein in the nervous system.
After over a decade in pre-clinical development, this first human trial of huntingtin-lowering drug began in late 2015, led by Professor Sarah Tabrizi (UCL Institute of Neurology) and sponsored by Ionis Pharmaceuticals.
The trial involved enrolling 46 patients with early Huntington’s disease at nine study centres in the UK, Germany and Canada.
Each patient received four doses of either IONIS-HTTRx or placebo, given by injection into the spinal fluid to enable it to reach the brain. As the phase 1/2a trial progressed, the dose of IONIS-HTTRx was increased several times according to the ascending-dose trial design.
Patient safety was monitored throughout the study by an independent safety committee.
Today’s announcement at completion of the trial confirms that IONIS-HTTRx was well-tolerated by the trial participants and its safety profile supports further testing in patients.
Professor Tabrizi, Director of the UCL Huntington’s Disease Centre and IONIS-HTTRx Global Chief Investigator, said: “The results of this trial are of ground-breaking importance for Huntington’s disease patients and families. For the first time a drug has lowered the level of the toxic disease-causing protein in the nervous system, and the drug was safe and well-tolerated. The key now is to move quickly to a larger trial to test whether the drug slows disease progression.”
A major unknown was whether the trial would show that IONIS-HTTRx could lower the level of mutant huntingtin protein in the nervous system. Using an ultra-sensitive assay, concentrations of the protein were measured in each patient’s spinal fluid before and after treatment.
As hoped, IONIS-HTTRx produced significant, dose-dependent lowering of the level of mutant huntingtin – the first time the protein known to cause Huntington’s has been lowered in the nervous system of patients.
As a result of these successful outcomes, Ionis’ partner, Roche, has exercised its option to license IONIS-HTTRx and assumes responsibility for further development, regulatory activities and commercialization activities. Meanwhile, Ionis announced in June that all patients in the completed trial would be offered a place in an open-label extension to receive IONIS-HTTRx.
Learn more: Drug lowers deadly Huntington’s disease protein
The Latest on: Huntington’s disease
- Huntington’s Disease benefit dinner set on April 18, 2019 at 9:00 pm
The Maher family of Sherman will present its 14th annual “Huntington's Disease Benefit Dinner: The Fred Maher's Family Journey” April 27 from 5:30 to 9:30 p.m. at the Bantam Fire Department, 92 Doyle ... […]
- Gene therapy could be a cure for 'bubble boy' disease on April 17, 2019 at 11:11 pm
New hope for a grim disease SCID-X1 is caused by a mutation in a gene called ... Dr. Michael Grosso, chair of pediatrics and chief medical officer at Northwell Health's Huntington Hospital in ... […]
- Drug used to treat high blood pressure could relieve Parkinson's, Huntington's and Alzheimer's on April 17, 2019 at 11:05 pm
A common feature of these conditions is misfolded proteins, such as huntingtin in Huntington's disease and tau in some forms of dementia, the authors wrote in the journal Nature Communications. These ... […]
- Baton Rouge walk to raise money for Huntington’s Disease victims on April 17, 2019 at 8:34 am
BATON ROUGE, LA (WAFB) - The Huntington’s Disease Society of America is organizing a fundraising walk to support HDSA’s fight to improve the lives of people and their families affected by the disease. ... […]
- Charles River Labs, CHDI Foundation pen boosted Huntington's disease pact on April 16, 2019 at 6:05 am
Charles River Laboratories and the privately funded, nonprofit biomedical research organization CHDI Foundation have signed a five-year extension for their Huntington’s disease work. This pact goes ... […]
- Huntington's Disease Illinois Chapter hosts 15th annual Team Hope Walk May 19 on April 15, 2019 at 7:05 pm
The Illinois Chapter of the Huntington's Disease Society of America recently announced that volunteers are raising awareness of this devastating genetic neurological disease through their community ... […]
- EIP bags cash to trial ex-Vertex drug in dementia, Huntington's on April 15, 2019 at 6:10 am
EIP Pharma has raised $11.2 million to expand its clinical trial activities beyond Alzheimer's disease. The cash will fund midphase trials of an ex-Vertex drug in dementia and Huntington's disease. ... […]
- Identifying Predictors of Suicidal Behavior in Huntington Disease on April 12, 2019 at 4:50 am
Researchers sought to identify variables that were associated with suicidal ideation or behavior in patients with Huntington disease. Psychiatric comorbidities are predictors of suicidal behavior in ... […]
- Wave slips behind in Huntington’s disease antisense race on April 11, 2019 at 3:31 pm
Slower-than-expected recruitment in trials of two of Wave Life Sciences’ experimental therapies of Huntington’s disease will delay results, and lengthen the gap with a rival drug from Roche ... […]
- This Appalachian town was America’s ‘fattest city.’ Here’s how it slimmed down. on April 10, 2019 at 8:58 am
In 2008, a study by the Centers for Disease Control and Prevention called Huntington, W.Va., the fattest city in America. The story was national news, a cautionary tale for a country whose waistline ... […]
via Google News and Bing News